Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry by Rossignol, Patrick et al.
European Journal of Heart Failure. 2020 
Unravelling the interplay between hyperkalaemia, renin–
angiotensin–aldosterone inhibitor use and clinical outcomes. 
Data from 9222 chronic heart failure patients of the ESC‐HFA‐
EORP Heart Failure Long‐Term Registry 
Patrick Rossignol1, Mitja Lainscak2, Maria G. Crespo-Leiro3, Cécile Laroche4, 
Massimo F. Piepoli5, Gerasimos Filippatos6, Giuseppe M.C. Rosano7, Gianluigi 
Savarese8, Stefan D. Anker9, Petar M. Seferovic10, Frank Ruschitzka11, Andrew J.S. 
Coats7, Alexandre Mebazaa12, Theresa McDonagh13, Ana Sahuquillo14, Maria 
Penco15, Aldo P. Maggioni4,16, and Lars H. Lund17, on behalf of the Heart Failure 
Long-Term Registry Investigators Group18 
1. Université de Lorraine, Centre d’Investigation Clinique Plurithématique 1433-INSERM-CHRU de Nancy, 
Inserm U1116 & FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France;  
2. Division of Cardiology, General Hospital Murska Sobota, Murska Sobota and Faculty of Medicine, 
University of Ljubljana, Ljubljana, Slovenia; 
3. Unidad de Insuficiencia Cardiaca y Trasplante Cardiaco, Complexo Hospitalario Universitario A Coruna 
(CHUAC), INIBIC, UDC, CIBERCV, La Coruna, Spain; 
4.  EURObservational Research Programme, European Society of Cardiology, Sophia-Antipolis, France;  
5.  Heart Failure Unit, Cardiac Department, G. da Saliceto Hospital, AUSL Piacenza, Italy; 
6.  School of Medicine, University of Cyprus & Heart Failure Unit, Department of Cardiology, University 
Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece; 
7. IRCCS San Raffaele Pisana, Rome, Italy; 
8. Division of Cardiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; Heart and 
Vascular Theme, Karolinska University Hospital, Stockholm, Sweden;  
9. Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies 
(BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité 
Universitätsmedizin, Berlin, Germany; 
10. University of Belgrade Faculty of Medicine, Belgrade, Serbia; 
11. University Hospital, Clinic of Cardiology, Zurich, Switzerland;  
12. UMR 942 Inserm MASCOT, Université de Paris; APHP Saint Louis Lariboisière University Hospitals, 
Department of Anesthesia-Burn-Critical Care, and FCRIN INI-CRCT (Cardiovascular and Renal Clinical 
Trialists), Paris, France; 
13. King’s College Hospital, London, UK 
14. Hospital de Manacor, Balearic Island, Spain;  
15. Cardiology University of L’Aquila, L’Aquila, Italy;  
16. ANMCO Research Center, Florence, Italy; and  
17. Unit of Cardiology, Department of Medicine, Karolinska Institutet, and Heart and Vascular Theme, 
Karolinska University Hospital, Stockholm, Sweden 









We assessed the interplay between hyperkalaemia (HK) and renin–angiotensin–aldosterone system inhibitor 
(RAASi) use, dose and discontinuation, and their association with all‐cause or cardiovascular death in patients 
with chronic heart failure (HF). We hypothesized that HK‐associated increased death may be related to RAASi 
withdrawal. 
 
Methods and results 
 
The ESC‐HFA‐EORP Heart Failure Long‐Term Registry was used. Among 9222 outpatients (HF with reduced 
ejection fraction: 60.6%, HF with mid‐range ejection fraction: 22.9%, HF with preserved ejection fraction: 
16.5%) from 31 countries, 16.6% had HK (≥5.0 mmol/L) at baseline. Angiotensin‐converting enzyme inhibitor 
(ACEi) or angiotensin receptor blocker (ARB) was used in 88.3%, a mineralocorticoid receptor antagonist 
(MRA) in 58.7%, or a combination in 53.2%; of these, at ≥50% of target dose in ACEi: 61.8%; ARB: 64.7%; 
and MRA: 90.3%. At a median follow‐up of 12.2 months, there were 789 deaths (8.6%). Both hypokalaemia 
and HK were independently 
associated with higher mortality, and ACEi/ARB prescription at baseline with lower mortality. MRA 
prescription was not retained in the model. In multivariable analyses, HK at baseline was independently 
associated with MRA non‐prescription at baseline and subsequent discontinuation. When considering 
subsequent discontinuation of RAASi (instead of baseline use), HK was no longer found associated with all‐





In HF, hyper‐ and hypokalaemia were associated with mortality. However, when adjusting for RAASi 
discontinuation, HK was no longer associated with mortality, suggesting that HK may be a risk marker for 
RAASi discontinuation rather than a risk factor for worse outcomes. 
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Introduction 
Renin–angiotensin–aldosterone system inhibitors (RAASi) [i.e. angiotensin-converting enzyme 
inhibitors (ACEis), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists 
(MRAs), and angiotensin receptor–neprilysin inhibitors], and beta-blockers are the cornerstones of 
therapy in patients with chronic heart failure (CHF) with reduced ejection fraction (HFrEF). Based 
on the highest level of evidence, they are strongly recommended in international guidelines (class 
IA1) for improving survival, decreasing sudden death, and preventing heart failure (HF) 
hospitalisations in patients with HFrEF.2 International registry data have shown that adherence to 
guideline recommended medications in HFrEF is associated with improved outcomes.3 However, 
guidelines are not being implemented,4 both in terms of overall use and target doses, often because 
of actual, or concerns for potential adverse events.2,5,6 Hyperkalaemia (HK), hypotension, 
deterioration of renal function, higher age and poor access to cardiologist care are the most 
frequently cited reasons for underdosing, underuse and discontinuation of RAASi in patients with 
HFrEF2,3,5,7,8 and at the same time, potassium is poorly monitored,9 even though benefits of RAASi 
appear as important in patients with severe chronic kidney disease10 and older age.11  
The European Society of Cardiology Heart Failure Association EURObservational Research 
Programme (ESC-HFA-EORP) Heart Failure Long-Term (HF-LT) Registry identified HK, 
impaired kidney function and hypotension as the main causes for non-prescription or underdosing 
of RAASi.7  
 
In a recent observational study including all Stockholm citizens initiating MRA therapy, the 
development of HK within a year was associated with a four-fold significantly higher risk in overall 
mortality, with the results being consistent in the subpopulation of patients with HF. Following the 
occurrence of HK, 47% discontinued MRA whereas only 10% reduced the prescribed dose. 
Strikingly, when MRA was discontinued, most patients (76%) were not reintroduced to MRA 
therapy during the subsequent year.8 Reintroduction of RAASi is less likely the longer the break in 
therapy.12 Therefore, HK, beyond its potentially lethal pro-arrhythmogenic properties, may be both 
a biomarker of RAASi under-use and under-dosing, a barrier to RAASi use, and a trigger for 
subsequent RAASi discontinuation, with all potentially being associated with poor outcomes in 
various populations,13 including HF.14  
 
We hypothesize that HK-associated increased death may be related to RAASi withdrawal. 
Therefore, using the ESC-HFA-EORP HF-LT Registry, we aimed to assess the interplay between 
HK (and its determinants), RAASi prescription and dosing at baseline, RAASi discontinuation, and 
associations with outcomes in outpatients with CHF enrolled in the HF-LT Registry. 
Methods 
Data source and study population 
The primary objective of the ESC-HFA-EORP HF-LT Registry is the description of the clinical 
epidemiology of HF outpatients and inpatients in ESC and affiliated countries, as well as the 
diagnostic and therapeutic processes used in the care of these patients. All national cardiology 
societies affiliated to the ESC were invited to participate.7,15 The ESC-HFA-EORP HF-LT Registry 
is a prospective, multicentre, observational registry of patients referred to a broad range of 
cardiology centres in 31 countries. The 31 countries are Belarus, Bulgaria, Croatia, Czech Republic, 
Georgia, Hungary, Moldova, Poland, Romania, Serbia, Slovakia, Slovenia (Eastern countries), 
Israel (Middle East), Egypt (North Africa), Denmark, Estonia, Latvia, Lithuania, Sweden 
(Northern), Bosnia Herzegovina, Cyprus, Greece, Italy, Kosovo, Macedonia, Portugal, Spain, 
Turkey (Southern), Austria, France, Switzerland (Western). The study design has previously been 
described.7,16 Briefly, there were no specific exclusion criteria, with the exception of age, which had 
to be greater than 18 years. Patients were followed up in accordance with the usual practice of the 
centres, with the exception of a mandatory follow-up visit at 12 months to collect information on 
morbidity and mortality. In cases where the patient was unable to reach the clinical centre, a phone 
survey replaced this follow-up clinical visit. The HF-LT Registry was approved by each local ethics 
board and written informed consent obtained in accordance with each country’s legislation. Random 
audits were conducted in each participating country. The HF-LT Registry enrolled all the outpatients 
with CHF seen at the clinics and those admitted to hospital for acute HF (either pre-existing or new-
onset HF) for whom intravenous HF therapy (diuretics, inotropes, or vasodilators) was used.16 
Patients were enrolled 1 day per week for 12 consecutive months.7  
 
In the current analysis only HF outpatients (i.e. CHF) were considered. Compared to the previous 
publications where 7401 CHF patients were described,7,16 a total of 9222 patients could now be 
described at the time the present research question was first addressed (2017). RAASi target doses 
were defined as in the ESC HF guidelines related to HFrEF.1 Patients who were receiving a RAASi 
dose ≥50% of the target dosage were compared to those who received <50% or no treatment. This 
threshold was based on the recent observation in the European setting that patients reaching <50% 
of the recommended ACEi/ARB (and beta‐blocker) dose displayed an increased risk of death and/or 
HF hospitalisation. Patients reaching 50–99% of the recommended ACEi/ARB and/or beta‐blocker 
dose had a comparable risk of death and/or HF hospitalisation to those reaching ≥100%.17 
Statistical analyses 
Descriptive statistics were used to summarise frequency tabulations (n , %) and distributions 
(median, interquartile range). Categorical variables were compared using the Chi‐square test or 
Fisher exact test, and continuous variables with a non‐parametric test (Kruskal–Wallis test). 
Predictors of mineralocorticoid receptor antagonist use 
Because MRAs is the RAASi category most affecting potassium homeostasis18 and also the least 
likely to be started and the most likely to be stopped in HF,19 we assessed predictors of (i) non‐use 
or at low dose at baseline, and (ii) MRA discontinuation during the follow‐up. In order to investigate 
why patients had low doses of MRAs or were without MRAs at baseline or with subsequent MRA 
discontinuation at 1‐year follow‐up, logistic regression models were performed with a stepwise 
procedure, using a P ‐value <0.05 to allow entry in the model and a P ‐value <0.05 to remain in the 
updated model. Independent variables that were significant at univariable analysis (P  < 0.10) as well 
as variables considered of relevant clinical interest were included at the beginning in the 
multivariable model. Potential interactions between baseline characteristics and baseline kalaemia 
(as a categorical variable) were tested. For the logistic regression model, MRA discontinuation 
corresponds to patients with any MRA agent at baseline but not at 1‐year follow‐up (i.e. stopped 
during the 1‐year follow‐up or at the 1‐year follow‐up visit). 
Outcomes 
For all‐cause and cardiovascular death, Cox regression models including baseline potassium 
level were performed using the same stepwise procedure as in the logistic regression models. Two 
different models were performed: (i) including ARBs, ACEis and MRAs, separately, as use vs. non‐
use at the baseline, and (ii) comparing RAASi use at baseline but not at follow‐up (i.e. discontinued) 
and, separately, no use of RAASi at baseline and at follow‐up with RAASi use at baseline and at 1‐
year follow‐up. In addition, natural cubic splines were presented for the unadjusted association 
between potassium levels and outcomes. 
 
Finally, three mediations analyses were performed20 for ACEi, ARB or MRA discontinuation, 
where the ‘direct effect’ was the direct effect of the potassium level on overall/cardiovascular 
mortality, meaning if significant that the potassium level directly impacts the mortality. The ‘indirect 
effect’ means that the potassium level has an impact on MRA/ACEi/ARB discontinuation, which 
has its own impact on mortality. 
 
P ‐value <0.05 was used as a cut‐off for statistical significance. All analyses were performed in 
SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA). 
  
Results 
Between April 2011 and May 2017, 19 136 patients were included in the HF‐LT Registry. Of 
these, 8290 (43.3%) were inpatients hospitalised with a diagnosis of acute HF and 10 846 (56.7%) 
were outpatients with CHF. Among outpatients, baseline potassium values were available in 9222 
(85.0%) patients (supplementary Figure S1 ), who represented our study population, and of whom 
16.6% had HK at baseline (≥5.0 mmol/L). Over a median follow‐up of 371 days (363–427), there 
were 789 deaths (8.6%), 241 (2.6%) patients lost to follow‐up, and 410 cardiovascular deaths (4.4%, 
or 52% of all deaths) as well as 195 deaths (2.1%, or 25% of all deaths) from unknown causes. 
 
Patient baseline features are presented in Table 1. In this mixed population of HFrEF (60.6%), 
HF with mid‐range (HFmrEF) (22.9%) and preserved ejection fraction (HFpEF) (16.5%), with the 
latter two without any guideline recommendation for RAASi,2 most patients were treated with an 
ACEi or an ARB (88.3%), an MRA (58.7%), or a combination thereof (53.2%), mostly at doses 
≥ 50% (ACEi: 61.8% ≥ 50% of the target dose; ARB: 64.7%; MRA: 90.3%). After 1 year, the 
frequency was 57.5%, 23.5%, 79.1% and 54.3% for ACEi, ARB, ACEi/ARB and MRA, 
respectively. 
Factors associated with RAASi prescription and dosing at baseline, or RAASi discontinuation 
Patients with HK at baseline were older, more frequently men, with diabetes and lower estimated 
glomerular filtration rate compared to normokalaemic patients (4.0–5.0 mmol/L). There were no 
significant differences in the proportion of patients with HFrEF, HFmrEF or HFpEF across the 
potassium strata (Table 1). ACEi use was more common in mildly hyperkalaemic (5–5.5 mmol/L) 
patients while MRA use was more common in normokalaemic patients. The co‐prescription of 
ACEi/ARB and MRA was less common in patients with serum potassium ≥5.5 mmol/L. While the 
percentage of ACEi or ARB target dose at baseline did not differ significantly across the potassium 
categories, hyperkalaemic patients were 2–3 times more frequently prescribed an MRA at <50% of 
the target dose at baseline (Table 1). Hyperkalaemic patients were also more prone to undergo 




























Table 1. Patient baseline characteristics and renin–angiotensin–aldosterone system inhibitor maintenance after 1 year 
 
Variable Total (n = 9222) <3 mmol/L (n = 
14, 0.2%) 
3–4 mmol/L 
(n =1431, 15.5%) 
4–5 mmol/L 
(n =6249, 67.8%) 
5–5.5 mmol/L 
(n =1202, 13.0%) 
≥5.5 mmol/L 
(n = 326, 3.5%) 
P ‐value 
Age (years), median (Q1–Q3) 67 (58–75) 56.5 (46–68) 67 (56–75) 66 (57–75) 69 (60–76) 69 (62–78) <0.001 
Female sex, n (%) 2646/9222 (28.7) 5/14 (35.7) 471/1431 (32.9) 1779/6249 (28.5) 305/1202 (25.4) 86/326 (26.4) <0.001 
Body mass index (kg/m2), median (Q1–Q3) 27.5 (24.6–30.9) 27.3 (25.4–31.1) 27.3 (24.2–30.8) 27.6 (24.6–30.9) 27.4 (24.6–31.0) 26.8 (24.4–30.5) 0.141 
SBP (mmHg), median (Q1–Q3) 120 (110–138) 120 (90–144) 120 (110–138) 120 (110–138) 120 (110–139) 120.5 (110–140)  
HR (bpm), median (Q1–Q3) 70 (62–80) 89 (71–105) 70 (63–81) 70 (61–80) 70 (60–79) 70 (63–81) <0.001 
Last known ejection fraction class (%), n (%)        
<40% 5073/8369 (60.6) 4/12 (33.3) 749/1236 (60.6) 3445/5685 (60.6) 678/1128 (60.1) 197/308 (64.0) 0.580 
40–50% 1918/8369 (22.9) 4/12 (33.3) 275/1236 (22.2) 1315/5685 (23.1) 259/1128 (23.0) 65/308 (21.1)  
>50% 1378/8369 (16.5) 4/12 (33.3) 212/1236 (17.2) 925/5685 (16.3) 191/1128 (16.9) 46/308 (14.9)  
NYHA class, n (%)        
I 1512/9197 (16.4) 2/14 (14.3) 198/1420 (13.9) 1058/6236 (17.0) 209/1201 (17.4) 45/326 (13.8) <0.001 
II 5213/9197 (56.7) 7/14 (50.0) 771/1420 (54.3) 3549/6236 (56.9) 695/1201 (57.9) 191/326 (58.6)  
III 2288/9197 (24.9) 4/14 (28.6) 420/1420 (29.6) 1510/6236 (24.2) 278/1201 (23.1) 76/326 (23.3)  
IV 184/9197 (2.0) 1/14 (7.1) 31/1420 (2.2) 119/6236 (1.9) 19/1201 (1.6) 14/326 (4.3)  
Pulmonary rales, n (%) 1365/8934 (15.3) 2/14 (14.3) 250/1369 (18.3) 894/6038 (14.8) 166/1189 (14.0) 53/324 (16.4) 0.015 
Peripheral oedema, n (%) 1859/8945 (20.8) 8/14 (57.1) 354/1371 (25.8) 1216/6047 (20.1) 215/1191 (18.1) 66/322 (20.5) <0.001 
Primary aetiology, n (%)        
Dilated cardiomyopathy 2585/9171 (28.2) 3/14 (21.4) 382/1421 (26.9) 1790/6210 (28.8) 324/1201 (27.0) 86/325 (26.5) 0.053 
Hypertension 777/9171 (8.5) 1/14 (7.1) 125/1421 (8.8) 516/6210 (8.3) 101/1201 (8.4) 34/325 (10.5)  
Ischaemic heart disease 3956/9171 (43.1) 3/14 (21.4) 588/1421 (41.4) 2670/6210 (43.0) 547/1201 (45.5) 148/325 (45.5)  
Other 931/9171 (10.2) 4/14 (28.6) 149/1421 (10.5) 628/6210 (10.1) 124/1201 (10.3) 26/325 (8.0)  
Tachycardia‐related cardiomyopathy 132/9171 (1.4) 0/14 (0.0) 30/1421 (2.1) 85/6210 (1.4) 13/1201 (1.1) 4/325 (1.2)  
Valve disease 790/9171 (8.6) 3/14 (21.4) 147/1421 (10.3) 521/6210 (8.4) 92/1201 (7.7) 27/325 (8.3)  
Atrial fibrillation, n (%) 3545/9221 (38.4) 8/14 (57.1) 604/1430 (42.2) 2350/6249 (37.6) 448/1202 (37.3) 135/326 (41.4) 0.006 
Stroke/TIA, n (%) 860/9213 (9.3) 1/14 (7.1) 127/1428 (8.9) 594/6246 (9.5) 105/1199 (8.8) 33/326 (10.1) 0.853 
Diabetes class, n (%) 2988/9222 (32.4) 5/14 (35.7) 400/1431 (28.0) 1959/6249 (31.3) 484/1202 (40.3) 140/326 (42.9) <0.001 
Hypertension treatment, n (%) 5523/9208 (60.0) 9/14 (64.3) 859/1427 (60.2) 3703/6239 (59.4) 730/1202 (60.7) 222/326 (68.1) 0.034 
Peripheral vascular disease, n (%) 1149/8936 (12.9) 0/14 (0.0) 161/1370 (11.8) 793/6040 (13.1) 144/1188 (12.1) 51/324 (15.7) 0.139 
Chronic kidney dysfunction, n (%) 1870/9213 (20.3) 2/14 (14.3) 259/1425 (18.2) 1145/6246 (18.3) 327/1202 (27.2) 137/326 (42.0) <0.001 
ICD, n (%) 1468/9203 (16.0) 1/14 (7.1) 223/1425 (15.6) 1018/6237 (16.3) 180/1201 (15.0) 46/326 (14.1) 0.525 
CRT‐P/D, n (%) 1236/9203 (13.4) 2/14 (14.3) 202/1425 (14.2) 828/6237 (13.3) 165/1201 (13.7) 39/326 (12.0) 0.823 
eGFR (mL/min/1.73 m2), median (Q1–Q3) 62.9 (46.6–79.9) 64.8 (49.3–77.6) 65.0 (49.5–81.2) 64.6 (48.6–81.5) 55.5 (41.0–73.0) 43.6 (29.9–61.4) <0.001 
eGFR (mL/min/1.73 m2) in class, n (%)        
<30 604/8583 (7.0) 1/14 (7.1) 79/1281 (6.2) 335/5824 (5.8) 111/1153 (9.6) 78/311 (25.1) <0.001 
30–60 3278/8583 (38.2) 5/14 (35.7) 457/1281 (35.7) 2122/5824 (36.4) 546/1153 (47.4) 148/311 (47.6)  
>60 4701/8583 (54.8) 8/14 (57.1) 745/1281 (58.2) 3367/5824 (57.8) 496/1153 (43.0) 85/311 (27.3)  
ACEi, n (%) 6066/9210 (65.9) 4/14 (28.6) 879/1431 (61.4) 4154/6239 (66.6) 822/1201 (68.4) 207/325 (63.7) <0.001 
ARB, n (%) 2234/9218 (24.2) 1/14 (7.1) 349/1431 (24.4) 1510/6245 (24.2) 294/1202 (24.5) 80/326 (24.5) 0.680 
ACEi/ARB, n (%) 8129/9210 (88.3) 5/14 (35.7) 1201/1431 (83.9) 5559/6239 (89.1) 1089/1201 (90.7) 275/325 (84.6) <0.001 
Beta‐blockers, n (%) 8197/9217 (88.9) 8/14 (57.1) 1234/1431 (86.2) 5582/6244 (89.4) 1100/1202 (91.5) 273/326 (83.7) <0.001 
MRA, n (%) 5412/9218 (58.7) 8/14 (57.1) 838/1431 (58.6) 3725/6245 (59.6) 702/1202 (58.4) 139/326 (42.6) <0.001 
ACEi/ARB and MRA, n (%) 4907/9216 (53.2) 4/14 (28.6) 721/1431 (50.4) 3395/6244 (54.4) 661/1202 (55.0) 126/325 (38.8) <0.001 
Diuretics oral, n (%) 7684/9217 (83.4) 13/14 (92.9) 1242/1431 (86.8) 5149/6244 (82.5) 1014/1202 (84.4) 266/326 (81.6) 0.001 
Ivabradine, n (%) 815/8958 (9.1) 0/14 (0.0) 116/1376 (8.4) 560/6052 (9.3) 114/1192 (9.6) 25/324 (7.7) 0.496 
Digitalis, n (%) 1982/9214 (21.5) 6/14 (42.9) 337/1430 (23.6) 1340/6242 (21.5) 223/1202 (18.6) 76/326 (23.3) 0.007 
Statins, n (%) 5646/9218 (61.2) 4/14 (28.6) 796/1431 (55.6) 3845/6245 (61.6) 806/1202 (67.1) 195/326 (59.8) <0.001 
ACEi target dose, n (%)        
< 50% max dosage 2195/5743 (38.2) 3/4 (75.0) 338/827 (40.9) 1483/3937 (37.7) 296/782 (37.9) 75/193 (38.9) 0.254 
≥ 50% max dosage 3548/5743 (61.8) 1/4 (25.0) 489/827 (59.1) 2454/3937 (62.3) 486/782 (62.1) 118/193 (61.1)  
ARB target dose, n (%)        
< 50% max dosage 666/1885 (35.3) 0/1 (0.0) 105/290 (36.2) 464/1283 (36.2) 76/250 (30.4) 21/61 (34.4) 0.446 
≥ 50% max dosage 1219/1885 (64.7) 1/1 (100.0) 185/290 (63.8) 819/1283 (63.8) 174/250 (69.6) 40/61 (65.6)  
MRA target dose, n (%)        
< 50% max dosage 511/5253 (9.7) 0/8 (0.0) 69/807 (8.6) 310/3611 (8.6) 104/690 (15.1) 28/137 (20.4) <0.001(S) 
≥ 50% max dosage 4742/5253 (90.3) 8/8 (100.0) 738/807 (91.4) 3301/3611 (91.4) 586/690 (84.9) 109/137 (79.6)  
ACEi/ARB discontinuation, n v(%) 949/7045 (13.5) 1/4 (25.0) 159/1001 (15.9) 600/4830 (12.4) 141/963 (14.6) 48/247 (19.4) <0.001 
ACEi discontinuation, n (%) 914/5237 (17.5) 1/3 (33.3) 147/724 (20.3) 580/3599 (16.1) 142/726 (19.6) 44/185 (23.8) 0.002 
ARB discontinuation, n (%) 418/1962 (21.3) 0/1 (0.0) 69/301 (22.9) 268/1326 (20.2) 53/261 (20.3) 28/73 (38.4) 0.006 
Beta‐blocker discontinuation, n (%) 787/7161 (11.0) 2/7 (28.6) 137/1040 (13.2) 495/4890 (10.1) 110/979 (11.2) 43/245 (17.6) <0.001 
MRA discontinuation, n (%) 890/4748 (18.7) 2/7 (28.6) 135/701 (19.3) 583/3295 (17.7) 130/618 (21.0) 40/127 (31.5) <0.001 
 
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CRT-P/D, cardiac resynchronization therapy with pacemaker or defibrillator; eGFR,  
estimated glomerular filtration rate; HR, heart rate; ICD, implantable cardioverter-defibrillator; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association;  











Figure 1 Multivariable analysis for clinical predictors of low dosage of mineralocorticoid receptor antagonists at baseline. 
Number of patients with complete data and included in the analysis: 5188/5253. Logistic regression with reference ≥50% 
target dose. BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; SBP, systolic 
blood pressure. 
Multivariable analyses did not confirm an association between baseline potassium categories and 
no use or low‐dose use of ACEi or ARB at baseline, while lower systolic blood pressure, ejection 
fraction >50% (vs. <40%) (for ACEi drug class) and renal dysfunction (for both drug classes) were 
found significantly and independently associated with no use or low‐dose use at baseline (data not 
shown). In multivariable analysis, hyperkalaemic patients (5–5.5 mmol/L vs. 4–5 mmol/L) and 
≥5.5 mmol/L vs. 4–5 mmol/L) and patients with renal dysfunction, along with those with higher 
systolic blood pressure were more prone to receive lower doses or no MRA at baseline (Figure 1). 
 
In multivariable analyses, lower blood pressure and kidney dysfunction were significantly 
associated with subsequent discontinuation of ACEi/ARB while potassium levels were not (data not 
shown). In contrast, renal dysfunction and potassium levels (HK ≥5.5 mmol/L) were associated with 
MRA discontinuation, along with other factors such as older age, ejection fraction >50% vs. <40%, 













Figure 2. Multivariable analysis for treatment discontinuation of mineralocorticoid receptor antagonists during 1‐year 
follow‐up. Number of patients with complete data and included in the analysis: 4408/4748. BMI, body mass index; CI, 
confidence interval; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; PVD, peripheral vascular disease; 
TIA, transient ischaemic attack. 
Factors associated with clinical outcomes 
In univariable analysis, a U‐shaped relationship was observed between baseline potassium and risk 
of all‐cause death (Figure 3A ), with a statistically significant association above approximately 
5 mmol/L for HK and <4 mmol/L for hypokalaemia. In multivariable analysis, HK ≥5.5 mmol/L 
remained associated with greater risk of death [hazard ratio (HR) 1.40 (1.02–1.92), P = 0.038], as 
was hypokalaemia [3–4 mmol/L; HR 1.26 (1.02–1.55), P = 0.031], while ACEi and/or ARB 
prescriptions at baseline were associated with better outcomes [HR 0.70 (0.57–0.86), P  < 0.001; HR 






Figure 3. (A ) Relationship between baseline serum potassium and 1‐year all‐cause death – natural cubic spline without 






Figure 4. Baseline factors associated with all‐cause death in multivariable analysis considering renin–angiotensin–
aldosterone system inhibitor prescription at baseline. Number of patients with complete data and included in the analysis: 
8173/9222. ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CI, 
confidence interval; COPD, chronic obstructive pulmonary disease; CRT‐D, cardiac resynchronization therapy with 
defibrillator; EF, ejection fraction; MRA, mineralocorticoid receptor antagonist; PVD, peripheral vascular disease; SBP, 
systolic blood pressure; TIA, transient ischaemic attack. 
 
When considering RAASi (ACEi, ARB, MRA) baseline percent of target doses instead of only 
use vs. non‐use, the non‐prescription of ACEi performed significantly worse compared to the 
prescription of ACEi at lower than 50% of the target doses [HR 1.42 (1.13;1.79), P = 0.003], while 
the comparison between <50% and ≥ 50% target doses did not reach statistical significance. In this 
model, only baseline hypokalaemia was associated with all‐cause mortality [HR 1.25 (1.01–
1.56), P = 0.042]. 
 
When considering subsequent discontinuation of RAASi for adjustments (instead of baseline use or 
dose) and serum potassium at baseline, HK was no longer associated with risk of all‐cause death 
while all RAASi (ACEi, ARB, or MRA) discontinuations, regardless of class, were strongly 
associated with the outcomes (Figure 5). In a sensitivity univariable analysis, ACEi, ARB or MRA 
discontinuations were found associated with all‐cause death across the ejection fraction strata (i.e. 
<40%, 40–50%, >50%; data not shown). 
 
 
Figure 5. Baseline factors associated with all‐cause death in multivariable analysis considering renin–angiotensin–
aldosterone system inhibitor (RAASi) discontinuation during 1‐year follow‐up. Number of patients with complete data and 
included in the analysis: 7413/9222. Variables are the same as in the previous model but instead of RAASi treatment at 
baseline, RAASi treatment corresponds to RAASi treatment during the 1‐year follow‐up with for each treatment (three 
possibilities: discontinuation – no treatment at baseline – no discontinuation, with no discontinuation as reference). ACEi, 
angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CI, confidence interval; 
COPD, chronic obstructive pulmonary disease; CRT‐D, cardiac resynchronization therapy with defibrillator; EF, ejection 
fraction; MRA, mineralocorticoid receptor antagonist; PVD, peripheral vascular disease; SBP, systolic blood pressure; TIA, 
transient ischaemic attack. 
 
In further sensitivity analyses, cardiovascular rather than all‐cause deaths were considered. In 
univariable analysis, a U‐shaped relationship was observed between baseline potassium and risk of 
cardiovascular death (Figure 3B ), with a significant association for HK and hypokalaemia. 
However, serum potassium concentrations were not identified as a predictor of cardiovascular death 
in the multivariable models, while use of ACEi or ARB at baseline was associated with better 
outcomes (supplementary Table S1 ). When considering RAASi (ACEi, ARB, MRA) baseline 
target doses instead, only the non‐prescription of ACEi or ARB performed significantly worse 
compared to the prescription of ACEi or ARB lower than 50% of the target doses 
(supplementary Table S2 ). 
 
Again, as for all‐cause death, ACEi, ARB or MRA discontinuations were all associated with a 
higher risk also of cardiovascular death (supplementary Table S3 ). In a sensitivity univariable 
analysis, ACEi, ARB or MRA discontinuations were found associated with cardiovascular death 
across the ejection fraction strata (i.e. <40%, 40–50%, >50%; data not shown). 
 
Finally, three multivariable mediation analyses (for ACEi, or ARB, or MRA discontinuation, 
respectively) were performed. HK (>5.5 mmol/L) was associated with mortality and cardiovascular 
mortality by mediating discontinuation of ACEi (marginally significant for all‐cause death: P = 
0.059), ARB (not statistically significant), and MRA (P = 0.007 for total mortality; P = 0.080 for 
cardiovascular death) (supplementary Table S4 ). 
Discussion 
In this contemporary European outpatient HF cohort, with a high rate of patients treated with 
RAASi compared to other HF populations, the prevalence of HK was high (16.6%), while the 1‐
year outcome was poor (overall and cardiovascular death: 8.6% and 4.4%, respectively). Similar to 
a number of surveys in post‐discharge post‐acute HF,21, 22 chronic HFrEF23 and HFpEF24 patients, a 
U‐shape relationship between baseline serum potassium and all‐cause death and cardiovascular 
death was observed over 1‐year follow‐up in univariate analysis 
. 
In a multivariable model considering all deaths, both hypokalaemia and HK were associated with 
poor outcomes, while ACEi/ARB but not MRA prescription was found to be independently 
associated with better outcomes. The absence of association between MRA use and outcomes has 
been previously described in observational settings and is most likely due to residual unmeasured 
confounding, such as higher use of MRAs in patients with refractory oedema, ascites, liver disease, 
diuretic resistance, high‐dose diuretic use, and/or other factors associated with poor outcomes. 
However, in additional multivariable analyses, when considering RAASi doses at baseline or 
subsequent RAASi discontinuation – instead of considering RAASi prescription at baseline – only 
RAASi discontinuations (ACEi, ARB, or MRA) were found consistently associated with all‐cause 
and cardiovascular death, independent of serum potassium at baseline and, importantly, HK was no 
longer associated with the clinical outcomes. Moreover, in multivariable analyses, HK at baseline 
was found to be associated with MRA non‐prescription at baseline and with its subsequent 
discontinuation. Additional mediation analyses showed that HK ≥5.5 mmol/L was associated with 
mortality and cardiovascular mortality by mediating discontinuation of ACEi, ARB, MRA, although 
it was not statistically significant for all. This was actually much more significant for MRA and 
suggests that the HK is more important through MRA discontinuation than through ACEi/ARB 
discontinuation. 
 
Altogether, these data provide insights into the interplay between HK, RAASi use and clinical 
outcomes in real‐life HF settings. Indeed, they clearly depict the current dilemma facing the 
implementation of these life‐saving drugs, in particular MRAs, in routine practice. The present 
findings complement numerous previous reports from the HF‐LT Registry and from the Swedish 
Heart Failure Registry studying the reasons for non‐prescription of RAASi.5, 7, 19, 25 In the large 
majority of these cases, reported contraindications, a documented intolerance or concerns about 
potential intolerance (HK, worsening renal function, hypotension) were the main reasons for the 
non‐prescription of these drugs.7 From this HF‐LT Registry dataset, it was reported that the true rate 
of under‐treatment for ACEi/ARB and MRAs in this well treated population was 3.2% and 5.4%, 
respectively (compared to others4), at least in terms of RAASi use.7 We also previously reported 
that, with regard to the target dosages of these drugs, fewer than one‐third of the patients were 
currently prescribed the target dosages suggested by current guidelines: 29.3% for ACEis, 24.1% 
for ARBs, and 30.5% for MRAs.7 
 
For the present study, the threshold of 50% of the recommended ACEi/ARB (and beta‐blocker) 
was selected since in a recent European survey, patients receiving less displayed an increased risk 
of death and/or HF hospitalisation.17  
Altogether, these data confirm that HK in itself is a major barrier toward the implementation of, 
and importantly maintenance of RAASi and more specifically of MRA, since prescribers, in 
accordance with the guidelines, are not prone to use MRAs3, 26 or to discontinue them in presence of 
HK.8, 27 In other words, beyond its pro‐arrhythmogenic properties, HK could also be a risk marker 
that leads to suboptimal use of RAASi, in particular MRAs, which in turn is causative of poor 
outcomes, as also suggested by previous surveys,28 and as shown here for the first time, being a 
marker of discontinuation. Clinicians may be well served by recognizing the causes of RAASi 
underuse. The present analysis from the ESC‐EORP‐HFA HF‐LT Registry suggests that HK is 
harmful because it causes RAASi discontinuation and a similar study from the Swedish Heart Failure 
Registry suggests that HK is harmful because it causes RAASi avoidance and 
discontinuation.29 Together with a previous analysis from BIOSTAT‐CHF suggesting that HK is in 
itself not harmful but prevents RAASi up‐titration,30 it is becoming increasingly clear that the 
universally poor implementation of RAASi and especially MRA drugs in HFrEF is extensively 
driven by actual or concerns for HK.28 Whether the vicious circle surrounding HK, which is an 
inherent risk factor for RAASi under‐use, may be overcome by the availability of new potassium 
binders31, 32 and/or novel MRAs less prone to HK warrants prospective cardiovascular outcome 
trials. 
Limitations 
As previously acknowledged,7 there are limitations of this and other registry analyses. All centres 
were cardiology centres, potentially limiting generalizability to internal medicine and primary care. 
To mitigate this issue, the centres in HF‐LT Registry were selected in proportion to the size of the 
population of the participating countries, taking into account the different technological levels of the 
cardiology centres invited to participate.7 
 
More specifically in relation to the present analysis, observational data cannot establish causality. 
This is particularly relevant for the associations between RAASi use and better outcomes, where 
available randomized trials exist. Secondly, only baseline serum potassium and baseline target doses 
were considered, whereas we previously reported from this registry that, in approximately one third 
of the patients not achieving the target doses, a drug up‐titration was still ongoing,7 and neither the 
timing of RAASi discontinuation nor potassium levels thereafter were recorded. Third, the study 
population consisted of an amalgamation of HFrEF, HFmrEF and HFpEF patients (in whom target 
doses were derived from HFrEF recommendations). However, ACEi, ARB or MRA 
discontinuations were found associated with all‐cause and cardiovascular death across the ejection 
fraction strata (i.e. <40%, 40–50%, >50%). Fourth, sacubitril/valsartan was not considered, not 
being approved at the time of data collection, while its use may be associated with less frequent HK 
in MRA recipients.33 However, findings related to the combined use of ACEi/ARB/MRA match the 
latest findings in a recently described European dataset. Indeed, the Dutch CHECK‐HF registry of 
HFrEF patients observed that, between 2013 and 2016, 84% of patients were treated with 
ACEi/ARB and 56% with MRA, and approximately one‐half of the HFrEF patients taking the 
prescribed medication were receiving less than the target dose of MRAs and ACEi/ARB.34 
Conclusions 
In this large, contemporary, international CHF population, hyper‐ and hypokalaemia, as well as 
non‐use of ACEi/ARB were associated with worse outcomes. Importantly, after adjusting for 
discontinuation of a RAASi (ACEi/ARB or MRA), HK was no longer associated with increased 
risk, suggesting that HK may be a risk factor for RAASi discontinuation and through this association 
becoming a risk marker rather than a risk factor for worse outcomes.28 This was further confirmed 
by mediation analyses especially considering MRA discontinuation. HK, also at baseline, 
represented a major hurdle against MRA use, thus its treatment and/or the prevention of its 
(re)occurrence under RAASi treatment may represent a potential therapeutic target. 
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